Please login to the form below

Not currently logged in
Email:
Password:

drisapersen

This page shows the latest drisapersen news and features for those working in and with pharma, biotech and healthcare.

CHMP backs two rare disease therapies at April meeting

CHMP backs two rare disease therapies at April meeting

The importance of Brineura to the company has gained prominence after it was forced to ditch Duchenne muscular dystrophy drug drisapersen in the face of regulatory resistance to approval.

Latest news

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Licence. 935. Prosensa / BioMarin. Drisapersen – for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00.  Prosensa has been busy since drisapersen failed a

  • Pharma deals during January 2014 Pharma deals during January 2014

    Terminations. Not surprisingly after the report of the failure of drisapersen in showing improvement in its phase III six minute walking study in Duchenne muscular dystophy, GSK announced the return of ... the drisapersen rights to Prosensa.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics